AGC is aiming to make $1.5 billion in sales by 2025 and says it will continue to actively invest in facilities around the world to bolster its CDMO presence. Contract development manufacturing organization (CDMO) AGC says its groups’ life science business forms part of its strategic initiative to aim for sales in the 200-billion-yen ($1.5 billion) range by 2025. “We aim to be the first provider that customer call on when they are looking for a CDMO in various fields…
Ilya Pharma has acquired its long-term partner Nordic Bioanalysis, which it says will help them support the Advanced Therapy Medicinal Product (ATMP) space. The deal, of which no financial details have been disclosed, sees clinical stage immunotherapy firm Ilya Pharma acquire Nordic Bioanalysis (NBAB), which develops pharmaceuticals and biologics, including antibodies and ATMPs. “NBAB mainly provide bioanalytical services for pharmaceuticals and medical devices. The advantages to Ilya Pharma are to de-risk our supply chain for CMC and clinical bioanalytics, the de-risking…